Kymera Therapeutics’ headquarters are located at 500 North Beacon Street, 4th Floor, Watertown, MA 02472.
Kymera Therapeutics was founded in 2016.
Kymera Therapeutics is incorporated in Delaware.
Kymera Therapeutics completed its IPO on August 20, 2020.
Kymera Therapeutics' fiscal year ends December 31st.
Kymera Therapeutics’ common stock is listed on the NASDAQ Market under the symbol “KYMR”.
The transfer agent and registrar for the common stock of Kymera Therapeutics’ stock is:
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
(800) 962-4284
For questions about your stock please contact our transfer agent, Computershare Trust Company, N.A..
To change the address on your shareholder account you must send both your old and new addresses to our transfer agent, Computershare Trust Company, N.A., 250 Royall Street, Canton, Massachusetts 02021.
To transfer stock or replace a lost stock certificate, contact our transfer agent, Computershare Trust Company, N.A.
The auditor for Kymera Therapeutics is Ernst & Young LLP located in Boston, MA.
Legal counsel for Kymera Therapeutics is Goodwin Procter LLP, located in Boston, MA.
To find out more about Kymera Therapeutics visit their webpage at www.kymeratx.com.
Kymera Therapeutics’ press release archive can be viewed under the “News & Events” section of the “Investors” page and financial reports are available under the “SEC Filings” section located at our website: www.kymeratx.com.
Kymera Therapeutics’ SEC Filings can be found on www.sec.gov and are also available under the “SEC Filings” section of the “Investors” page located at our website www.kymeratx.com.
For a list of the Management team and Board of Directors, please visit the “About Us” section of our website.
For investor inquiries, please contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com